An interventional study of Ferrous sulphate 200mg oral tablet in Hereditary Haemorrhagic Telangiectasia, sponsored by Imperial College London. Terminated at 1 site in United Kingdom. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-09-26.
Sponsored by Imperial College London · Not applicable, Interventional, and Treatment
Managing iron deficiency is important for more than 1 billion individuals worldwide, to avoid blood transfusions, or excessive strain on vital organs that depend on iron-containing haemoglobin to deliver oxygen to the tissues. Iron deficiency is a particular problem for people with the inherited condition hereditary haemorrhagic telangiectasia (HHT). Their iron deficiency and anaemia results from blood losses, especially from the nose (nosebleeds, and they often need additional iron to replace that lost through bleeding.
Our goal is to stratify HHT patients into high/low absorbers of iron; to define what extra iron they need to adjust for their current and likely future blood losses; and to work out how to achieve this most safely for each individual to improve their later health.
We will test the hypothesis that informed assessment of iron intake and post absorption cellular profiles changes the recommendations for iron intake for HHT patients.
Relevant patients due to come to clinic or the programmed investigation unit will be offered the opportunity to participate in the study.
Up to 100 consenting individuals will
The primary outcome measure is the change in serum iron levels post iron tablet.
Other outcome measures will include:
106 studies on the registry are indexed under Telangiectasia, Hereditary Hemorrhagic; 24 are open to participants now.
This study's enrollment of 3 is below the median of 33 across 61 interventional studies indexed under Telangiectasia, Hereditary Hemorrhagic.
Browse Telangiectasia, Hereditary Hemorrhagic studies →Imperial College London is the lead sponsor of 843 studies on the registry; 180 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INTERVENTION: Ferrous sulphate 200mg oral tablet This is a single arm study. Individuals in this arm will * have an additional 15 mls of supplementary research bloods taken with their usual clinic bloods * receive a single tablet of ferrous sulphate 200mg * fill in questionnaires that formally evaluate their nosebleed losses and dietary iron intake in the preceding 12 months * have a second blood sample later that day (20 mls of blood Total number of participants in arm = 100
Drug: Ferrous sulphate 200mg oral tablet
Administration by mouth
Also known as: Iron tablet
Blood iron indices
Time frame: 4-5 hours after iron tablet ingestion
Ran from Jul 2013 to primary completion in Jul 2015, 24 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ferrous sulfate
Telangiectasia, Hereditary Hemorrhagic →